We are live on ! Find out more
BLU

BELLUS Health Inc.
BLU

Delisted

BLU was delisted on the 28th of June, 2023.

Back to rankings

64 hedge funds and large institutions have $376M invested in BELLUS Health Inc. in 2020 Q2 according to their latest regulatory filings, with 24 funds opening new positions, 20 increasing their positions, 12 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more first-time investments, than exits

New positions opened: 24 | Existing positions closed: 8

67% more repeat investments, than reductions

Existing positions increased: 20 | Existing positions reduced: 12

33% more funds holding

Funds holding: 48 → 64 (+16)

13% more capital invested

Capital invested by funds: $334M → $376M (+$42.2M)

50% less funds holding in top 10

Funds holding in top 10: 4 → 2 (-2)

Holders
64
Holders Change
+16
Holders Change %
+33.33%
% of All Funds
1.31%
Holding in Top 10
2
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-50%
% of All Funds
0.04%
New
24
Increased
20
Reduced
12
Closed
8
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
CAC
Cowen and Company
New York
+$15.7M
2
EAM
Eventide Asset Management
Massachusetts
+$15.6M
3
PA
Perceptive Advisors
New York
+$11.4M
4
MWNA
Marshall Wace North America
New York
+$9.68M
5
RSCM
Rock Springs Capital Management
Maryland
+$7.06M

Top Sellers

Rank Fund Capital Flow
1
O
OrbiMed
New York
-$19.1M
2
PC
Polar Capital
United Kingdom
-$16M
3
Adage Capital Partners
Adage Capital Partners
Massachusetts
-$5.99M
4
EGI
EAM Global Investors
California
-$5.44M
5
First Manhattan
First Manhattan
New York
-$4.08M
Name Holding Trade Value Shares
Change 		Change in
Stake
Royal Bank of Canada
51
Royal Bank of Canada
Ontario, Canada
$39K – – –
AA
52
AlphaCentric Advisors
Puerto Rico
$37K +$36.5K +3,600 New
Canada Life
53
Canada Life
Manitoba, Canada
$35K +$35.2K +3,473 New
ClearBridge Investments
54
ClearBridge Investments
New York
$27K – – –
Toronto Dominion Bank
55
Toronto Dominion Bank
Ontario, Canada
$26K +$25.6K +2,521 +252,100%
LC
56
Lindbrook Capital
California
$12K +$10.1K +1,000 +641%
UBS Group
57
UBS Group
Switzerland
$10K -$2.28K -225 -18%
Legal & General Group
58
Legal & General Group
United Kingdom
$9K +$9.29K +917 New
SAM
59
Shell Asset Management
Netherlands
$5K +$4.63K +457 New
Osaic Holdings
60
Osaic Holdings
Arizona
$5K +$5.07K +500 New
TRCT
61
Tower Research Capital (TRC)
New York
$5K +$5.21K +514 New
TFS
62
TrustCore Financial Services
Tennessee
$2K +$1.01K +100 +143%
GCM
63
Gables Capital Management
Florida
$1K – – –
Adage Capital Partners
64
Adage Capital Partners
Massachusetts
– -$5.99M -600,000 Closed
EGI
65
EAM Global Investors
California
– -$5.44M -544,795 Closed
CA
66
Corriente Advisors
Texas
– -$1.48M -148,666 Closed
EI
67
EAM Investors
California
– -$727K -72,811 Closed
IC
68
Ikarian Capital
Texas
– -$891K -63,721 Closed
ERSOT
69
Employees Retirement System of Texas
Texas
– -$621K -62,270 Closed
JP Morgan Chase
70
JP Morgan Chase
New York
– -$294K -29,438 Closed
FC
71
FORA Capital
Florida
– -$27K -2,693 Closed
1 2
3

BLU Hedge Fund Activity: Q2 2020 in Review

64 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in BELLUS Health Inc. (BLU) for Q2 2020, worth a combined $376M — up 13% from $334M a quarter earlier.

Buyers outnumbered sellers: 24 funds opened new BLU positions and 8 closed out — a net gain of 16 holders — while 20 added to existing stakes and 12 trimmed.

The largest buyer was Cowen and Company, adding an estimated $15.7M. The largest seller was OrbiMed, cutting an estimated $19.1M.

  • 64 institutional investors held BELLUS Health Inc. (BLU) as of Q2 2020, up from 48 in Q1 2020.
  • Funds reported $376M of BELLUS Health Inc. stock for Q2 2020, up 13% quarter-over-quarter.
  • 24 funds opened new BELLUS Health Inc. positions in Q2 2020 and 8 closed out, a net change of +16 holders.
  • The largest BELLUS Health Inc. buyer in Q2 2020 was Cowen and Company, an estimated $15.7M added.
  • The largest BELLUS Health Inc. seller in Q2 2020 was OrbiMed, an estimated $19.1M sold.

Based on aggregated 13F filings for Q2 2020.